Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 24.
doi: 10.1038/s41587-025-02814-6. Online ahead of print.

Deep-learning-based virtual screening of antibacterial compounds

Affiliations

Deep-learning-based virtual screening of antibacterial compounds

Gabriele Scalia et al. Nat Biotechnol. .

Erratum in

  • Publisher Correction: Deep-learning-based virtual screening of antibacterial compounds.
    Scalia G, Rutherford ST, Lu Z, Buchholz KR, Skelton N, Chuang K, Diamant N, Hütter JC, Luescher JM, Miu A, Blaney J, Gendelev L, Skippington E, Zynda G, Dickson N, Koziarski M, Bengio Y, Regev A, Tan MW, Biancalani T. Scalia G, et al. Nat Biotechnol. 2025 Nov 7. doi: 10.1038/s41587-025-02941-0. Online ahead of print. Nat Biotechnol. 2025. PMID: 41203993 No abstract available.

Abstract

The increase in multidrug-resistant bacteria underscores an urgent need for additional antibiotics. Here, we integrate small-molecule high-throughput screening with a deep-learning-based virtual screening approach to uncover new antibacterial compounds. We screen ~2 million small molecules against a sensitized Escherichia coli strain, yielding thousands of hits. We use these data to train a deep learning model, GNEprop, to predict antibacterial activity, retrospectively validating robustness with respect to out-of-distribution generalization and activity cliff prediction. Virtual screening of over 1.4 billion synthetically accessible compounds identifies potential candidates, of which 82 exhibit antibacterial activity on the same strain, illustrating a 90-fold improved hit rate over the high-throughput screening experiment used for training. Many newly identified compounds exhibit high dissimilarity to known antibiotics, potency beyond the training bacterial strain and selectivity. Biological characterization identifies specific, validated targets, indicating promising avenues for further exploration in antibiotic discovery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: G.S., S.T.R., Z.L., K.R.B., N.S., K.C., J-C.H., J.B., L.G., E.S., A.R, M.-W.T. and T.B. are employees of Genentech and shareholders of Roche. Y.B. is an advisor for Recursion Pharmaceuticals. A.R. is a cofounder and equity holder of Immunitas and, until July 31, 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. The other authors declare no competing interests.

References

    1. Mayr, L. M. & Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 9, 580–588 (2009). - PubMed - DOI
    1. Martin, J. K. 2nd et al. A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance. Cell 181, 1518–1532 (2020). - PubMed - PMC - DOI
    1. Imai, Y. et al. A new antibiotic selectively kills gram-negative pathogens. Nature 576, 459–464 (2019). - PubMed - PMC - DOI
    1. Scherlach, K. & Hertweck, C. Mining and unearthing hidden biosynthetic potential. Nat. Commun. 12, 3864 (2021). - PubMed - PMC - DOI
    1. Sellés Vidal, L., Isalan, M., Heap, J. T. & Ledesma-Amaro, R. A primer to directed evolution: current methodologies and future directions. RSC Chem. Biol. 4, 271–291 (2023). - PubMed - PMC - DOI

LinkOut - more resources